<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03352765</url>
  </required_header>
  <id_info>
    <org_study_id>17-373</org_study_id>
    <nct_id>NCT03352765</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients</brief_title>
  <official_title>A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is testing a combination of chemo-immuno therapy called RBM. RBM consists of&#xD;
      combination of drugs: rituximab, bendamustine, and melphalan followed by reinfusion of the&#xD;
      participants own stem cells which is called autologous stem cell transplant (ASCT). Compared&#xD;
      to the standard BEAM regimen, this RBM regimen may or may not be less effective in lymphoma,&#xD;
      but will likely have fewer side effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a phase I single arm, open label trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicities (DLT)</measure>
    <time_frame>1 year</time_frame>
    <description>are defined as grade &gt; 3, non-hematologic toxicity related to treatment excluding grade 3 nausea or vomiting responsive to anti-emetic treatment, grade 3 diarrhea responding to anti-diarrheal treatment, grade 3 fatigue, grade 3 skin rash responsive to topical or systemic steroids, grade 3 fevers (&gt; 40 degrees Celsius for &lt; 24 hours) and alopecia per CTCAE</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>rituximab, bendamustine &amp; melphalan and ASCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a phase I study of rituximab, bendamustine and melphalan (RBM) conditioning followed by ASCT in elderly patients with B-cell NHL. Conditioning regimen consist of rituximab 375 mg/m2 on days -11 and -4, bendamustine 160 mg/m2 intravenously on days -3 and -2; melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0. The conditioning timeline can be modified if there are patient scheduling conflicts. Patients who are deemed inevaluable will be replaced for the primary objective. Patients will be considered inevaluable if they don't receive one dose of conditioning regimen and are removed from the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>rituximab 375 mg/m2 on days -11 and -4, The second dose of rituximab (day -4) is administered 7 days after the first dose (day -11), +/- 1 day. Rituximab may be administered by a local oncologist. If the participant has a CD20 negative tumor, rituximab can be omitted from the conditioning regimen.</description>
    <arm_group_label>rituximab, bendamustine &amp; melphalan and ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bendamustine</intervention_name>
    <description>bendamustine 160 mg/m2 intravenously on days -3 and -2</description>
    <arm_group_label>rituximab, bendamustine &amp; melphalan and ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0.</description>
    <arm_group_label>rituximab, bendamustine &amp; melphalan and ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Stem Cell Transplantation (ASCT)</intervention_name>
    <description>reinfusion of autologous stem cells on day 0.</description>
    <arm_group_label>rituximab, bendamustine &amp; melphalan and ASCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Phase I eligibility:&#xD;
&#xD;
          -  Any patient with multiple myeloma B-cell non-Hodgkin lymphoma would be eligible for&#xD;
             phase I portion of the study.&#xD;
&#xD;
        Dose expansion eligibility:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of multiple myeloma or rel/ref DLBCL, or diffuse&#xD;
             large B cell lymphoma transformed from an indolent lymphoma Since the endpoint of the&#xD;
             Phase I portion is safety, any patient with myeloma or B-cell NHL can be enrolled. For&#xD;
             dose expansion study patients with myeloma and B-NHL will be analyzed separately. The&#xD;
             PFS endpoint varies greatly amongst different types of lymphoma. In order to&#xD;
             accurately interpret the survival data as secondary endpoint, a homogeneous cohort of&#xD;
             patients with DLBCL will be evaluated. DLBCL is the most aggressive B-NHL with limited&#xD;
             options. Other B-NHL's are generally more indolent and have more options available to&#xD;
             them.&#xD;
&#xD;
        Additional eligibility for both the phase I and dose expansion cohort:&#xD;
&#xD;
          -  Patients between the ages of 65 to 69 years old with a Hematopoietic Stem Cell&#xD;
             Transplant Comorbidity Index (HCT-CI) score of 3 or higher.&#xD;
&#xD;
          -  Any patient age 70 years old or older, irrespective of their Hematopoietic Stem Cell&#xD;
             Transplant Comorbidity Index (HCT-CI) score.&#xD;
&#xD;
          -  KPS ≥ 70&#xD;
&#xD;
          -  Males must agree to use an acceptable form of contraception per institutional&#xD;
             practices.&#xD;
&#xD;
          -  Complete or partial response to salvage chemotherapy by IWG Working Group Criteria&#xD;
&#xD;
          -  Cardiac ejection fraction of ≥ 45%&#xD;
&#xD;
          -  Hemoglobin-adjusted diffusing capacity of carbon monoxide (DLCO) of ≥45%&#xD;
&#xD;
          -  Creatinine clearance of ≥50 mL/min&#xD;
&#xD;
          -  Completion of most recent salvage therapy within 8 weeks of enrollment&#xD;
&#xD;
          -  Direct bilirubin ≤2.0 mg/dL in the absence of suspected Gilbert's disease (if&#xD;
             Gilbert's disease is suspected, the total bilirubin must be ≤3.0 mg/dL), and AST ≤ 2.5&#xD;
             ULN.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In Lymphoma: Disease progression by IWG Working Group Criteria since last therapy&#xD;
&#xD;
          -  Patients with history of CNS involvement&#xD;
&#xD;
          -  Prior autologous (only in lymphoma) or allogeneic stem cell transplantation&#xD;
&#xD;
          -  Patients who have failed bendamustine-based regimen previously&#xD;
&#xD;
          -  Patients within 6 months of MI and stroke will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parastoo Dahi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Parastoo Dahi, MD</last_name>
    <phone>212-639-5846</phone>
    <email>dahip@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Hamlin, MD</last_name>
    <phone>908-542-3366</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parastoo Dahi, MD</last_name>
      <phone>212-639-5846</phone>
    </contact>
    <contact_backup>
      <last_name>Paul Hamlin, MD</last_name>
      <phone>908-542-3366</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 21, 2017</study_first_submitted>
  <study_first_submitted_qc>November 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2017</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rituximab</keyword>
  <keyword>Bendamustine</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Autologous Stem Cell Transplantation (ASCT)</keyword>
  <keyword>17-373</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

